Clinical Trial Update: A Phase I - II Safety Study of Filgrastim (Neupogen) to Improve Left Ventricular Function After Severe Acute Myocardial Infarction [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase I–II safety study evaluated whether filgrastim (Neupogen) can improve left ventricular function after acute myocardial infarction.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Infarction

Drugs mentioned

• Filgrastim (Neupogen) (filgrastim)

Snippet

Sponsor: The Cleveland Clinic | Conditions: Acute Myocardial Infarction | Phase 1, Phase 2 | Status: COMPLETED